

Discovery of PIP5Kgamma inhibitor for treatment of Parkinson's disease



NEUROSCIENCE	Hit
Product Type	Small molecule
Indication	Early Parkinson's disease, Juvenile Parkinson's disease (SYNJ1 mutation)
Target	PIP5Kg
MoA(Mechanism of Action)	PIP5Kg inhibition > Inhibition of α -syn aggregation and ROS production > neuroprotection
Competitiveness	<ul style="list-style-type: none"> • First in class • Discovery of highly selective and potent PIP5Kg inhibitor protect cell death in the differentiated dopaminergic cells (SH-SY5Y, LUHMES) and primary rat mesencephalic neuronal cells • Inhibition of α-syn aggregation
Development Stage	Hit
Route of Administration	Oral administration